Skip to main content
Premium Trial:

Request an Annual Quote

Large Scale Biology Shares Up Despite 58-Percent Plunge in Q3 Revenue

This article has been updated to include share price.

NEW YORK, Nov. 4 (GenomeWeb News) - Shares in Large Scale Biology were up 3.16 percent at $.98 despite a 58-percent plunge in third-quarter revenue.

 

LSB, owner of Predictive Diagnostics, today said that third-quarter revenue fell to $500,000 from $1.2 million one year ago. The Vacaville, Calif.-based company did not break out figures for its wholly owned biomarker-company subsidiary.

 

LSB attributed the severe decline to the loss of $800,000 in revenues generated during the third quarter of 2003 by its Germantown, Md.-based contract proteomics business, which it closed last November (see ProteoMonitor, GenomeWeb News' sister publication).

The company spent $2.3 million on R&D in the period, down slightly from $2.7 million year over year.

Consequently, net losses for the third quarter narrowed to $4.2 million, or $.13 per share, from $4.3 million, or $.17 per share, in 2003.

 

The results do not include one full quarter of activity related to Predictive Diagnostics' agreement with PerkinElmer, which the companies announced in late September. Under the agreement, PerkinElmer will offer the Predictive Diagnostics' Biomarker Amplification Filter technology to complement its own prOTOF 2000 MALDI O-TOF mass spectrometer.

LSB ended the quarter with $3.9 million in cash and marketable securities.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.